Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. - Wikidata - wikimedia - TriplyDB

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.

http://www.wikidata.org/entity/Q34323951

about

Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options Targeted therapy for HER2 positive breast cancer Ten things you should know about protein kinases: IUPHAR Review 14 Targeted therapy in advanced bladder cancer: what have we learned?Profile of neratinib and its potential in the treatment of breast cancer The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.Activating HER2 mutations in HER2 gene amplification negative breast cancer Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.What is known about melatonin, chemotherapy and altered gene expression in breast cancer HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines.Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer.Perspectives: Other ErbB2-Targeted Therapies.Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer.Phosphoproteomics in cancer Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.Targeted inhibition of kinases in cancer therapy

P2860

Q21132316-C42EAC9C-1360-403A-ABFA-C41DD2A25122 Q24617184-B32CFE21-FA02-48A2-BA2F-A39D6CEB0BF3 Q24649935-FDA58FB6-B58B-4D59-A4B1-2383737171EA Q26777681-71979721-D90C-4C9C-8F7D-219F021D6F08 Q26830496-D726DB99-E37C-478F-994E-A37483A2691F Q26849417-CF34C4A5-7A4F-4E54-91A6-3B535D9B6C9F Q27009469-1AE03603-8B2B-4B51-A155-3679858B4E1D Q27012540-133310F6-D727-42DA-94E7-C2423E9B137E Q27021738-59F3C122-2683-41CD-8285-2AF232D8B574 Q27025863-D9401850-EB1C-4F63-BDE3-F1DC1C3D9DD3 Q27649889-A495AB0E-B634-4F36-B2E5-5D69A6E75697 Q27851628-31F5B3EC-B0DC-453D-B8A8-3882A8B818F5 Q27851691-552CC277-EC48-4DFA-B6B0-2970A0B7B446 Q27851987-64643DDC-13A8-45FB-9ECE-EAF02F047AB2 Q27853060-335B1773-AD5E-46DA-8D0E-FB8AC9FAAC69 Q28071303-89FA1097-9C95-4A6F-B890-AA0F142D8F7C Q28079320-ECB8DECC-3D36-4F96-A20E-EF839BC5214D Q28083239-21F0D40A-929D-454E-9812-4064EFE230C9 Q28084565-A2069AD3-151D-46BD-B26B-9FF6C8901334 Q28479059-D45965C1-E083-4248-B70C-F5AFD368D4BE Q28547522-CEC66D4D-43A0-4AA4-80D3-DF3BAE27C3BD Q33352155-F2105D16-28FF-453B-BC13-7491C6A518F5 Q33597963-3158ECA7-B848-428F-85A9-F3E0DF266691 Q33666849-7803C2EB-DC3F-4D63-8C05-DAC1248E830B Q33821320-93D7F8FB-55DA-477A-8566-1F053F0D47A7 Q33835904-49F9244B-6C24-4054-BF6C-26CFD67012F0 Q33906140-4F3298FF-51C9-469A-ACAC-EC7295C6C6B8 Q33916081-F9AD2E13-8577-481D-B657-10D23FE3B922 Q34023704-2656CCBA-ACE4-4338-9D46-4F7199B09FDE Q34096063-B47BE7A3-B8D6-4D06-97F2-291CDD88799B Q34096252-6CF8D10D-D6A6-43C5-9F70-9AAB43D0FAA4 Q34139691-E40CD3E3-BC37-4D73-8EC5-B15533BCC09C Q34268618-812D2E50-99CC-4A14-87C7-7975916F08DC Q34355748-7B5E1AE5-A4B6-4DC6-A926-29258BA1B92D Q34422576-59FD9FA4-BBA7-4351-9709-3738CE47EADD Q34433903-0532B910-4AF0-4BF9-9F25-E7268E99B9AF Q34539788-C09E6243-9E3C-4444-814B-2A2730D74A05 Q34570753-2F571D41-AF28-419E-8BD2-CE8EFAB6D3B3 Q34589789-CF7AB37C-B44C-4297-B706-61FFEA0E8CC2 Q34683348-045ED418-5763-4DA7-A1BE-0799BC486816

P2860

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.

http://www.wikidata.org/entity/Q34323951

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Antitumor activity of HKI-272, ...... of the HER-2 tyrosine kinase.

@ast

Antitumor activity of HKI-272, ...... of the HER-2 tyrosine kinase.

@en

Antitumor activity of HKI-272, ...... of the HER-2 tyrosine kinase.

@nl

type

label

Antitumor activity of HKI-272, ...... of the HER-2 tyrosine kinase.

@ast

Antitumor activity of HKI-272, ...... of the HER-2 tyrosine kinase.

@en

Antitumor activity of HKI-272, ...... of the HER-2 tyrosine kinase.

@nl

prefLabel

Antitumor activity of HKI-272, ...... of the HER-2 tyrosine kinase.

@ast

Antitumor activity of HKI-272, ...... of the HER-2 tyrosine kinase.

@en

Antitumor activity of HKI-272, ...... of the HER-2 tyrosine kinase.

@nl

P1433

Q34323951-9B26972D-D1E0-4530-85E5-A61B43E70F58

P1476

Q34323951-90C7F4AA-9F85-4F9C-86D4-6705E4E6B3CF

P2093

Q34323951-0B32266C-2063-44BD-974C-59B04A76EC62

Q34323951-4A90EC02-95B8-4243-8D94-39381F6D4B8F

Q34323951-4AD64D3C-8132-46FF-A111-9204172D4578

Q34323951-4D3AFB77-6F7D-47BE-ADAA-A0F768EED5DB

Q34323951-5BD3BA50-4751-4AC3-ACF8-9A0CDB59D0DA

Q34323951-77517BCF-4354-43D4-B67D-7299B2D42878

Q34323951-A5CC3322-1892-41C3-94C0-4F81012A5AA6

Q34323951-A6BB4D96-1210-441B-8572-464ACF23226E

Q34323951-ADA96BDD-EB05-442D-8853-0DB60847EB7B

Q34323951-C7060667-1B0D-4F1F-8E45-E6734B72AC59

P304

Q34323951-A9CB2928-8F32-40C0-8D4B-9328EBA3A324

P31

Q34323951-E4E183E7-35BB-4D17-B923-0DA7DC61AAE2

P356

Q34323951-5BCF76B4-69BB-4EE8-A589-C1A38F12DAC7

P407

Q34323951-033DD739-F5AC-4401-9D43-1FF40E7D6395

P433

Q34323951-C2D64BC3-8002-44A2-A0A8-FF841AEF855F

P478

Q34323951-DBDAEA59-900D-471A-9B41-4E0E57D3BD57

P577

Q34323951-C42D7A65-643A-46A6-81C5-BC19D27D434A

P698

Q34323951-AB0E470A-D681-4105-B581-BEE327DFF172

P356

0008-5472.CAN-03-2868

P1433

Cancer Research

P1476

Antitumor activity of HKI-272, ...... of the HER-2 tyrosine kinase.

@en

P2093

Allan Wissner

http://www.w3.org/2001/XMLSchema#string

Bernard D Johnson

http://www.w3.org/2001/XMLSchema#string

Carolyn M Discafani

http://www.w3.org/2001/XMLSchema#string

Edward C Rosfjord

http://www.w3.org/2001/XMLSchema#string

Elsebe Overbeek

http://www.w3.org/2001/XMLSchema#string

Hwei-Ru Tsou

http://www.w3.org/2001/XMLSchema#string

Jonathan Golas

http://www.w3.org/2001/XMLSchema#string

M Brawner Floyd

http://www.w3.org/2001/XMLSchema#string

Marvin F Reich

http://www.w3.org/2001/XMLSchema#string

Michelle Baxter

http://www.w3.org/2001/XMLSchema#string

P304

3958-3965

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-03-2868

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15173008

http://www.w3.org/2001/XMLSchema#string